Filing Analysis
Cryo-Cell International received notice that NYSE Regulation accepted its compliance plan to regain standing with NYSE American listing standards. The company has been granted a plan period until September 9, 2027, to meet the requirements and avoid delisting.
🚩 Red Flags
- The company is currently in violation of NYSE American continued listing standards.
- The long duration of the compliance period (extending into late 2027) suggests significant financial or structural hurdles to overcome.
- Delisting risk remains if the company fails to make progress consistent with the accepted plan.
📋 Key Facts
- Notice of plan acceptance received from NYSE Regulation on May 6, 2026.
- The compliance plan was originally submitted by the company on April 8, 2026.
- The company has until September 9, 2027, to regain compliance with listing standards.
- Common stock (CCEL) will continue to trade on NYSE American during the plan period subject to periodic review.
- Failure to meet plan milestones or the final deadline may result in immediate delisting proceedings.
Cryo-Cell International received a notice from NYSE American LLC on March 9, 2026, stating the company is not in compliance with continued listing standards under Section 1003(a). The company must submit a plan to regain compliance by April 8, 2026, to avoid potential delisting.
🚩 Red Flags
- Failure to satisfy continued listing standards.
- Risk of delisting if the compliance plan is not accepted or executed successfully.
- Potential underlying financial distress as Section 1003(a) often pertains to equity deficits or sustained losses.
📋 Key Facts
- Notice received from NYSE American on March 9, 2026.
- Non-compliance relates to Section 1003(a) of the NYSE American Company Guide.
- Deadline to submit a compliance plan is April 8, 2026.
- Common stock continues to trade on NYSE American under the symbol 'CCEL' during the plan review period.
- Section 1003(a) typically involves requirements regarding stockholders' equity and/or net losses.
Cryo-Cell International, Inc. announced that it will not declare a quarterly cash dividend for the fourth quarter of fiscal 2025. The company noted that future dividend decisions will depend on financial performance and strategic priorities.
🚩 Red Flags
- Suspension of dividend payments (though common in micro-caps to preserve cash).
📋 Key Facts
- The company will not declare a quarterly cash dividend for Q4 fiscal 2025.
- Dividend policy remains discretionary based on capital requirements and strategic priorities.
- Report filed on November 12, 2025.
Cryo-Cell International entered into a Fifth Amendment to its existing Credit Agreement with Susser Bank. The amendment extends the maturity date of the $10M Revolving Credit Facility (RCF) from October 2025 to October 2027 and modifies several terms including credit limits and interest margins.
🚩 Red Flags
- Reduction in revolving credit limit from $10M to $8M suggests tightened liquidity access.
- The RCF was previously extended only for a short period (July 2025 to October 2025), indicating potential recent liquidity pressure.
📋 Key Facts
- The RCF Note maturity date was extended from October 18, 2025, to October 18, 2027.
- The Term Note maturity date was extended to July 29, 2032.
- The Revolving Credit Limit was reduced from $10,000,000 to $8,000,000.
- Wholly owned subsidiary Celle Corp. has been added as a guarantor and executed a Security Agreement.
- Interest margins were revised: Term Loans (Base Rate + 4.25% / SOFR + 3.25%) and RCF (Base Rate + 3.75% / SOFR + 2.75%).
- A commitment fee of 0.25% is applicable.
The Company has announced the scheduling of its 2025 Annual Meeting of Stockholders. The meeting is set for October 21, 2025, with a record date of September 15, 2025.
📋 Key Facts
- Annual Meeting Date: October 21, 2025
- Record Date: September 15, 2025
- Notice for business/director nominations must be submitted by the 10th calendar day following public disclosure (September 20, 2025).
Cryo-Cell International, Inc. has received a notice of termination from Duke University regarding their Patent and Technology License Agreement, effective May 17, 2025. The termination is based on alleged breaches by Cryo-Cell following the company's own demand for arbitration against Duke.
🚩 Red Flags
- Loss of exclusive patent and technology licenses is critical to the company's core business model.
- Active litigation/arbitration with a key partner (Duke University) creates significant legal uncertainty.
- The termination stems from allegations of breach by Cryo-Cell, which could lead to further legal liabilities or damages.
📋 Key Facts
- Duke University issued a notice of termination of the Patent and Technology License Agreement on May 17, 2025.
- The original agreement was dated February 23, 2021.
- The license provided Cryo-Cell exclusive rights to commercially exploit certain licensed products and processes for treating/preventing diseases in humans.
- The termination follows a demand for arbitration filed by Cryo-Cell against Duke alleging fraudulent inducement and breach of contract.
Cryo-Cell International, Inc. announced a reduction in its quarterly cash dividend to $0.15 per share. The Board cited the current economic environment and alternative capital allocation needs for this decision.
🚩 Red Flags
- Dividend reduction may indicate tightening liquidity or a shift in cash flow priorities due to the 'current economic environment'.
📋 Key Facts
- Dividend amount: $0.15 per share of common stock.
- Record date: May 21, 2025.
- Payment date: Expected on May 30, 2025.
- Reasoning provided: Current economic environment and other capital allocation alternatives.
Cryo-Cell International, Inc. held its Annual Meeting of Stockholders on October 29, 2024. The meeting resulted in the election of four directors and the ratification of WIPFLI LLC as the company's independent auditor.
📋 Key Facts
- Annual Meeting of Stockholders held on October 29, 2024.
- Four directors were elected: David Portnoy (3,653,908 votes), Harold Berger (3,628,143 votes), Mark Portnoy (3,649,613 votes), and Daniel Mizrahi (4,072,486 votes).
- WIPFLI LLC was ratified as the independent registered public accounting firm for the fiscal year ending November 30, 2024.
- A non-binding advisory resolution regarding executive compensation was approved with 4,152,942 votes in favor.
Cryo-Cell International, Inc. has declared a cash dividend of $0.25 per share of common stock. The dividend is payable to shareholders of record as of November 15, 2024.
📋 Key Facts
- Dividend amount: $0.25 per share of common stock.
- Record date: Close of business on November 15, 2024.
- Payment date: Expected on November 29, 2024.
Cryo-Cell International, Inc. issued an 8-K to announce the release of its financial results for the three and nine months ended August 31, 2024.
📋 Key Facts
- The filing reports on results of operations and financial condition (Item 2.02).
- Reporting period covers the three and nine months ended August 31, 2024.
- The announcement was made via press release dated October 15, 2024.
Cryo-Cell International, Inc. has announced the scheduling of its 2024 Annual Meeting of Stockholders. The meeting is set for October 29, 2024, with a record date of September 20, 2024.
📋 Key Facts
- Annual Meeting Date: October 29, 2024
- Record Date: September 20, 2024
- Deadline for stockholder business/director nominations: Within 10 calendar days of the public disclosure date (September 17, 2024).
Cryo-Cell International announced plans to spin off its subsidiary, Celle Corp., to existing shareholders. Following the spin-off, the company intends to explore strategic alternatives including equity/debt financing or a potential sale/merger.
🚩 Red Flags
- Explicit mention of exploring 'equity and/or debt financings' suggests potential liquidity needs or dilution risk.
- The exploration of a 'possible sale or merger' often indicates a company in transition or facing capital constraints.
📋 Key Facts
- Planned spin-off of newly formed subsidiary 'Celle Corp.' to Cryo-Cell shareholders.
- Company is exploring all strategic alternatives post-spin-off to maximize shareholder value.
- Strategic alternatives explicitly include equity financing, debt financing, or a sale/merger of the company.
- Announcement date: March 25, 2024.